News & Media

SK Life Science

Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company

General business

Strategic alliance and partnership opportunities

Media inquiries and PR

Grant and investigator initiated proposals

Sponsorship requests

Medical information inquiries or report adverse events

SK Life Science at a glance

  • Headquarters location


  • R&D Begins


  • Parent Company

    SK Life Science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group

  • Number of employees

    200+ EMPLOYEES

  • Disease Category Focus


  • Pipeline

    8 compounds under clinical development


SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969

Full release

Expert Consensus Opinions Published in Neurology and Therapy Discuss Adjustment of Anti-Seizure Medication Dosing for Optimal Care

Full release

New Drug Filing for Cenobamate Accepted for Review in Canada and Israel

Full release

SK Biopharmaceuticals, Eurofarma Enter into Licensing Agreement for Cenobamate in Latin America

Full release

SK Biopharmaceuticals’ 2022 Sustainability Report Reinforces its Commitment to ESG Management

Full release

Long-Term Efficacy and Safety Data of XCOPRI® (cenobamate tablets) CV Published in Neurology

Full release

SK Biopharmaceuticals Announces Social Value Performance for 2021

Full release

SK Biopharmaceuticals Partners with Cala to Fuel Innovation in Neurology

Full release

SK life science Presents Long-term Data on Cognitive and Psychiatric Adverse Events Associated with XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset (Focal) Seizures at the AAN 2022 Annual Meeting

Full release

SK life science to Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Academy of Neurology 2022 Annual Meeting

Full release